Bertilimumab
Encyclopedia
Bertilimumab is a human
monoclonal antibody that binds to eotaxin-1.
It was discovered by Cambridge Antibody Technology
using their phage display
technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis
.
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza
, in its cGMP facilities in Slough
, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.
Human
Humans are the only living species in the Homo genus...
monoclonal antibody that binds to eotaxin-1.
It was discovered by Cambridge Antibody Technology
Cambridge Antibody Technology
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, United Kingdom...
using their phage display
Phage display
Phage display is a method for the study of protein–protein, protein–peptide, and protein–DNA interactions that uses bacteriophages to connect proteins with the genetic information that encodes them. Phage Display was originally invented by George P...
technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis
Keratoconjunctivitis
Keratoconjunctivitis is inflammation of the cornea and conjunctiva.When only the cornea is inflamed, it is called keratitis; when only the conjunctiva is inflamed, it is called conjunctivitis....
.
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza
Lonza Group
Lonza Group is a Swiss chemicals and biotechnology company, headquartered in Basel. The firm provides a number of products and services to the pharmaceutical and life science industries, including organic fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis...
, in its cGMP facilities in Slough
Slough
Slough is a borough and unitary authority within the ceremonial county of Royal Berkshire, England. The town straddles the A4 Bath Road and the Great Western Main Line, west of central London...
, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.